(Q37713730)

22 August 2017

1 reference

title

Type I interferon therapy and its role in autoimmunity (English)

1 reference

22 August 2017

3

Pier Luigi Meroni

1 reference

22 August 2017

1

Martina Biggioggero

1 reference

22 August 2017

Lisa Gabbriellini

2

1 reference

22 August 2017

publication date

1 April 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

43

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

248-254

1 reference

Interferons, interferon-like cytokines, and their receptors

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Side effects of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Interferon-alpha as maintenance therapy in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Maintenance therapy with interferon alfa 2b in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Antifibrotic therapy in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Systemic sclerosis: hypothesis-driven treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Recombinant interferon gamma therapy for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Interferon beta for rheumatoid arthritis: new clothes for an old kid on the block.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Syndromes and complications of interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Autoimmune aspects of cytokine and anticytokine therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Thyroid autoimmunity and dysfunction associated with type I interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Induction of clinical autoimmune disease by therapeutic interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Side effects of high-dose interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Alpha-interferon-induced arthritis: clinical presentation treatment, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

21 January 2018

Statement on Sarcoidosis

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Interferon alpha associated with systemic lupus erythematosus is not intrinsically acid labile

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

The central role of dendritic cells and interferon-alpha in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Type I interferon and lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Three checkpoints in lupus development: central tolerance in adaptive immunity, peripheral amplification by innate immunity and end-organ inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Deficiency of the type I interferon receptor protects mice from experimental lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Interferon alpha-induced lupus: proof of principle

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Type I interferon correlates with serological and clinical manifestations of SLE

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Increased expression of the type I interferon-inducible gene, lymphocyte antigen 6 complex locus E, in peripheral blood cells is predictive of lupus activity in a large cohort of Chinese lupus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916930903510971

10.3109/08916930903510971

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference